
Alexander E Felice

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7188505/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Epigenomic analysis of KLF1 haploinsufficiency in primary human erythroblasts. Scientific Reports, 2022, 12, 336.	3.3	5
2	Immunoglobulin G in Platelet-Derived Wound Healing Factors. BioMed Research International, 2021, 2021, 1-16.	1.9	1
3	GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future Directions. Cancers, 2021, 13, 493.	3.7	14
4	A Functional Single Nucleotide Polymorphism in the AÎ ³ Globin Gene Promoter Affects Globin Chain Synthesis. Blood, 2020, 136, 20-20.	1.4	0
5	Genetic Heterogeneity of KLF1, a Master Regulator of Erythropoiesis, Revealed an Autosomal Recessive Î'β-Thalassemia and a Very Strong Promoter In Vivo. Blood, 2020, 136, 7-7.	1.4	0
6	ldentification of an HNF1A p.Gly292fs Frameshift Mutation Presenting as Diabetes During Pregnancy in a Maltese Family. Clinical Medicine Insights: Case Reports, 2019, 12, 117954761983103.	0.7	5
7	A Twenty-Five Year Prospective Clinical Review and Family Studies Revealed New Globin Gene Regulators for Hb F Induction. Hemoglobin, 2019, 43, 337-337.	0.8	0
8	Case Report: Identification of an HNF1B p.Arg527Gln mutation in a Maltese patient with atypical early onset diabetes and diabetic nephropathy. BMC Endocrine Disorders, 2018, 18, 28.	2.2	11
9	Genetic causes of Parkinson's disease in the Maltese: a study of selected mutations in LRRK2, MTHFR, QDPR and SPR. BMC Medical Genetics, 2016, 17, 65.	2.1	10
10	The EuroBioBank Network: 10 years of hands-on experience of collaborative, transnational biobanking for rare diseases. European Journal of Human Genetics, 2015, 23, 1116-1123.	2.8	63
11	Genomic variation in the <i>MAP3K5</i> gene is associated with β-thalassemia disease severity and hydroxyurea treatment efficacy. Pharmacogenomics, 2013, 14, 469-483.	1.3	25
12	<i>KLF10</i> gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients. Pharmacogenomics, 2012, 13, 1487-1500.	1.3	37
13	Sepiapterin reductase deficiency: A Treatable Mimic of Cerebral Palsy. Annals of Neurology, 2012, 71, 520-530.	5.3	125
14	Genetic factors in risk assessment for the development of type 2 diabetes mellitus in a small case series. International Journal of Risk and Safety in Medicine, 2011, 23, 119-123.	0.6	5
15	Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach. Nature Genetics, 2011, 43, 295-301.	21.4	142
16	Recommendations for genetic variation data capture in developing countries to ensure a comprehensive worldwide data collection. Human Mutation, 2011, 32, 2-9.	2.5	25
17	Erythroid phenotypes associated with KLF1 mutations. Haematologica, 2011, 96, 635-638.	3.5	78
18	Does Quantitative Heterogeneity of Human Fetal Hemoglobin (Hb F) Reveal Friends or Foes of KLF1 in Globin Gene Switching ?. Blood, 2011, 118, 1092-1092.	1.4	1

Alexander E Felice

#	Article	IF	CITATIONS
19	Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nature Genetics, 2010, 42, 801-805.	21.4	323
20	Hb Valletta [β87(F3)Thr→Pro] and Hb Marseille/Long Island [β2(NA2)His→Pro; (–1)Met-(+1)Val-(+2)Pro-Leu], a Unique Compound Heterozygote with a Normal Hemoglobin Phenotype. Hemoglobin, 2010, 34, 169-174.	in 0.8	1
21	KLF1 Dependent Pathways In Developmental Globin Gene Switching. Blood, 2010, 116, 5162-5162.	1.4	2
22	An Electronic Infrastructure for Research and Treatment of the Thalassemias and Other Hemoglobinopathies: The Euro-Mediterranean Ithanet Project. Hemoglobin, 2009, 33, 163-176.	0.8	23
23	Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study. Occupational and Environmental Medicine, 2007, 64, 666-672.	2.8	228
24	Gene-environment interactions in parkinsonism and Parkinson's disease: the Geoparkinson study. Occupational and Environmental Medicine, 2007, 64, 673-680.	2.8	93
25	Developmental Effect of theXmnl Site onGγ-Globin Gene Expression Among Newborn Hb F-Malta-I [Gγ117(G19)His→Arg, CAT→CGT] Heterozygotes and Adult β+-Thalassemia Homozygotes. Hemoglobin, 2007, 71-82.	301.8	4
26	A Review ofCis-TransInterplay Between DNA Sequences 5â€ ² to theGÎ ³ - and Î ² -Globin Genes Among Hb F-Malta-I Heterozygotes/Homozygotes and Î ² -Thalassemia Homozygotes/Compound Heterozygotes, and the Effects of Hydroxyurea on the Hb F/F-Erythrocyte; the Need for Large Multicenter Trials. Hemoglobin, 2007, 31, 279-288.	0.8	4
27	Molecular genetics of tetrahydrobiopterin (BH4) deficiency in the Maltese population. Molecular Genetics and Metabolism, 2007, 90, 277-283.	1.1	24
28	Population Structure in the Mediterranean Basin: A Y Chromosome Perspective. Annals of Human Genetics, 2006, 70, 207-225.	0.8	56
29	Sepiapterin reductase deficiency: a congenital dopa-responsive motor and cognitive disorder. Brain, 2005, 128, 2291-2296.	7.6	112
30	Novel Polymorphisms Influencing Transcription of the Human CHRM2 Gene in Airway Smooth Muscle. American Journal of Respiratory Cell and Molecular Biology, 2004, 30, 678-686.	2.9	35
31	international journal for hemoglobin research. Hemoglobin, 2003, 27, 137-137.	0.8	0
32	Treatment of leg ulcers with platelet-derived wound healing factor (pdwhfs) in a patient with beta thalassaemia intermedia. British Journal of Haematology, 2001, 112, 527-529.	2.5	17
33	Mutation screening of the muscarinic M2 and M3 receptor genes in normal and asthmatic subjects. British Journal of Pharmacology, 2001, 133, 43-48.	5.4	37
34	Comparativeln VivoExpression of \hat{l}^2 +-Thalassemia Alleles. Hemoglobin, 1999, 23, 221-229.	0.8	5
35	Characterization and locus assignment of two α-globin variants present in the maltese population: Hb St. Luke's [α95(G2)Pro→Arg] and Hb Setif [α94(G1)Asp→Tyr]. Hemoglobin, 1999, 23, 145-157.	0.8	6
36	Two new missense mutations (P134T and A244V) in the coagulation factor VII gene. Human Mutation, 1998, 11, S189-S191.	2.5	4

Alexander E Felice

#	Article	IF	CITATIONS
37	Guardianship by Peer Review in Genetic Engineering and Biotechnology. Philosophy and Medicine, 1998, , 117-129.	0.3	0
38	HB Setif [α94(GI)ASPÃTYR] in Malta. Hemoglobin, 1997, 21, 91-96.	0.8	5
39	Polymerase chain Reaction in molecular biotechnology; appropriate technology for developing countries. World Journal of Microbiology and Biotechnology, 1996, 12, 467-471.	3.6	0
40	The β+IVS, I-NT no. 6 (T→C) thalassaemia in heterozygotes with an associated Hb Valletta or Hb S heterozygosity in homozygotes from Malta. British Journal of Haematology, 1993, 83, 669-671.	2.5	20
41	The linkage of Hb Valletta [?2?287(F3)Thr?Pro] and Hb F-Malta-I [?2 G?2117(G19)His?Arg] in the Maltese population. Human Genetics, 1991, 86, 591-4.	3.8	16
42	Hb Evans or α ₂ 62(E11)Val→Metβ ₂ ; an Unstable Hemoglobin Causing a Mild Hemolytic Anemia. Hemoglobin, 1989, 13, 557-566.	0.8	23
43	Effects of α-thalassemia-2 on the developmental changes of hematological values in children with sickle cell disease from georgia. American Journal of Hematology, 1987, 25, 389-400.	4.1	22
44	Different ? globin gene deletions among Black Americans. Human Genetics, 1986, 73, 221-224.	3.8	42
45	(AγÎβ)°-Thalassaemia in Blacks is due to a deletion of 34 kbp of DNA. British Journal of Haematology, 1985, 59, 343-356.	2.5	36
46	Alternate Organization of α G-Philadelphia Globin Genes Among U.S. Black and Italian Caucasian Heterozygotes. Hemoglobin, 1984, 8, 537-547.	0.8	14
47	Identification and quantitation of embryonic and three types of fetal hemoglobin produced on induction of the human pluripotent leukemia cell line K-562 with hemin. American Journal of Hematology, 1982, 12, 1-12.	4.1	21
48	Organization of ?-chain genes among Hb G-Philadelphia heterozygotes in association with Hb S, ?-thalassemia, and ?-thalassemia-2. Biochemical Genetics, 1982, 20, 689-701.	1.7	31
49	The Occurrence and Identification of <i>α</i> -Thalassemia-2 among Hemoglobin S Heterozygotes. American Journal of Clinical Pathology, 1981, 76, 70-73.	0.7	8
50	In vitro synthesis of hemoglobin and hemoglobin chains in the BFUe-derived colonies from persons with α- or β-thalassemia. American Journal of Hematology, 1981, 10, 227-237.	4.1	9
51	?-Thalassemia and the production of different ? chain variants in heterozygotes. Biochemical Genetics, 1981, 19, 487-498.	1.7	9
52	Clinical and Hematological Evaluation of two δ ⁰ l´ ⁰ - Thalassemia Homozygotes. Hemoglobin, 1981, 5, 153-164.	0.8	9
53	Interaction of the β chain variant hemoglobin leslie and the α chain variant hemoglobin montgomery in a black female. American Journal of Hematology, 1980, 8, 139-147.	4.1	5
54	Adult and Fetal Hemoglobin Production in Erythroid Colonies from Subjects with β-Thalassemia or with Hereditary Persistence of Fetal Hemoglobin (HPFH). Hemoglobin, 1980, 4, 449-467.	0.8	8

ALEXANDER E FELICE

#	Article	IF	CITATIONS
55	Hb S, Hb G-PHILADELPHIA AND α-THALASSEMIA-2 IN A BLACK FAMILY. Pediatric Research, 1980, 14, 266-267.	2.3	14
56	Observations on the Calculated Contents of Variant and Normal α Chains in Adult and Fetal Erythrocytes. Hemoglobin, 1979, 3, 475-480.	0.8	7
57	The association of sickle cell anemia with heterozygous and homozygous α-thalassemia-2: In vitro HB chain synthesis. American Journal of Hematology, 1979, 6, 91-106.	4.1	31
58	Is the trimodality of Hb leslie (α2β2131Gln → 0) in heterozygotes the result of a variable number of active α-chain genes? Evidence for posttranslational control of hemoglobin synthesis. American Journal of Hematology, 1978, 5, 1-9.	4.1	11
59	Hb Nottingham (α;2β;2 (FG5) 98 VAL→GLY) in a Caucasian Male: Clinical and Biosynthetic Studies. Hemoglobin, 1978, 2, 315-332.	0.8	10
60	Îβ-Thalassemia in a Mexican Family: Clinical Differences Among Homozygotes. Hemoglobin, 1978, 2, 513-529.	0.8	12
61	Anomaly in the \hat{I}^3 chain heterogeneity of the newborn. Nature, 1977, 265, 63-65.	27.8	35
62	Detection and quantitation of the fetal hemoglobin variant Hb F-Malta-I in adults. Biochemical Genetics, 1977, 15, 915-923.	1.7	11